Tecan Group Past Earnings Performance
Past criteria checks 0/6
Tecan Group's earnings have been declining at an average annual rate of -25.5%, while the Life Sciences industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 0.9% per year.
Key information
-25.46%
Earnings growth rate
-26.64%
EPS growth rate
| Life Sciences Industry Growth | 17.57% |
| Revenue growth rate | 0.88% |
| Return on equity | -9.61% |
| Net Margin | -12.54% |
| Next Earnings Update | 11 Aug 2026 |
Recent past performance updates
Recent updates
TECN: AI Lab Collaboration And Execution Discipline Will Support Future Earnings
The analyst price target for Tecan Group has shifted slightly to around CHF 167, with recent CHF 1 and CHF 17 target reductions from different firms. These moves have led analysts to fine tune assumptions on discount rate, revenue growth, profit margin and future P/E, without changing the overall valuation picture in a major way.
TECN: Mixed Research Views And 2026 Guidance Shape Forward Expectations
Analysts have trimmed their average price target on Tecan Group to CHF 205, a CHF 17 reduction from recent levels. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions following mixed target moves across the Street.TECN: AI Lab Collaboration Will Support Forward Efficiency Gains And Earnings
The updated analyst price target for Tecan Group moves to CHF 166.50 from CHF 192.57, reflecting mixed Street views as some analysts trim targets while others highlight support from higher assumed revenue growth and a slightly lower future P/E multiple. Analyst Commentary Recent Street research on Tecan Group points to a split view, with some analysts trimming price targets and others turning more constructive on the shares.TECN: Mixed Research Views And Investor Day Outlook Shape Future Expectations
Analysts have trimmed their price target for Tecan Group to CHF 137.00 from CHF 165.20, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E. Recent research also includes both a Morgan Stanley target cut and target and rating adjustments from other firms.
TECN: Recent Upgrade And CHF 205 Goal Will Support Higher Long Term P/E
Analysts have nudged their price targets on Tecan Group slightly lower, with moves such as Morgan Stanley trimming its target by CHF 5 and others, including Bernstein and Berenberg, adjusting their outlooks. These revisions have led to only marginal changes in modeled fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.TECN: CFO Transition And Execution Will Support Higher Long Term P/E Potential
Analysts have nudged their price expectations for Tecan Group slightly higher, with the updated fair value estimate moving from CHF 334.71 to about CHF 335.08. This reflects small model adjustments to growth, margins and long term P/E assumptions after recent mixed target moves from banks that both lowered and raised their CHF based price targets.TECN: Execution And CFO Transition Will Support Upgraded Outlook And Medium Term Upside
Narrative Update The analyst price target for Tecan Group has been revised to CHF 205 from CHF 200. Analysts cite updated assumptions on growth, profitability and a higher future P/E multiple as the main factors behind this change.TECN: Efficiency Gains And Gradual Market Recovery Will Support Forward Earnings
Analysts have trimmed their price target on Tecan Group to about CHF 193 from around CHF 202, reflecting slightly lower fair value estimates, supported by recent target reductions such as the move to CHF 170 cited in Street research. Analyst Commentary Recent Street commentary around Tecan Group points to a more cautious stance, with price targets being reset closer to CHF 170, which sits below the trimmed average around CHF 193.Does Tecan Group (VTX:TECN) Have A Healthy Balance Sheet?
Dec 23
TECN: Medium Term Execution And CFO Transition Will Support Future Upside Potential
Analysts have lowered their price target on Tecan Group to CHF 170 from CHF 177, reflecting a slightly higher discount rate despite modestly improved revenue growth and profit margin expectations. Analyst Commentary Bullish analysts acknowledge the modest reduction in the price target but view the revised CHF 170 level as still supportive of upside potential from current trading levels, given improving fundamentals and execution.TECN: Efficiency Gains And Market Recovery Will Drive Forward Earnings Improvements
Analysts have reduced their price target for Tecan Group from CHF 177 to CHF 170. They cited revised market assumptions and modest adjustments to key financial forecasts as reasons for this change.TECN: Automation Demand And Partnerships Will Drive Earnings Recovery After 2026
Tecan Group: Analyst Price Target Reduced on Updated Outlook Analysts have lowered their fair value estimate for Tecan Group from CHF 205.98 to CHF 202.48. They cited slightly higher discount rates and tempered expectations for revenue growth and profit margins as reasons for the change.Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 90% Above Its Share Price
Nov 06TECN: Resilient Demand And Share Repurchase Program Will Drive Shareholder Value
The analyst price target for Tecan Group has been revised downward from CHF 177 to CHF 170. Analysts cite slightly softer revenue growth expectations and a modest increase in the discount rate in their updated assessments.Should You Investigate Tecan Group AG (VTX:TECN) At CHF150?
Oct 22Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Tecan Group's updated analyst fair value price target has been revised downward from CHF 215.73 to CHF 207.23. This change reflects cautious analyst views amid slower revenue growth and tightened profit margin expectations.Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Analysts have adjusted their price target for Tecan Group downward, reducing the fair value estimate from CHF 220.47 to CHF 215.73. This change is due to a slight increase in the discount rate, although forecasts for revenue growth and profit margins have improved.Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Analysts have lowered their outlook for Tecan Group due to concerns over near-term margin pressure, cautious end-market demand, and delayed recovery in key segments, though the consensus price target remained unchanged at CHF220.47. Analyst Commentary Cautious sentiment due to anticipation of "soft" first-half financial results impacting near-term performance.Tecan Group (VTX:TECN) Has A Pretty Healthy Balance Sheet
Sep 04Weak Statutory Earnings May Not Tell The Whole Story For Tecan Group (VTX:TECN)
Aug 20Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 08Why We're Not Concerned About Tecan Group AG's (VTX:TECN) Share Price
Jul 21At CHF170, Is Tecan Group AG (VTX:TECN) Worth Looking At Closely?
May 28Is Tecan Group AG (VTX:TECN) Trading At A 26% Discount?
Apr 24Tecan Group AG (VTX:TECN) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless
Apr 08Here's Why Shareholders Should Examine Tecan Group AG's (VTX:TECN) CEO Compensation Package More Closely
Apr 04Is Tecan Group (VTX:TECN) Using Too Much Debt?
Apr 01
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
Expansion into South Korea and FDA approval in Malaysia bolster Tecan's production and revenue growth potential in medical devices.Tecan Group AG's (VTX:TECN) Share Price Could Signal Some Risk
Jan 12A Look At The Fair Value Of Tecan Group AG (VTX:TECN)
Dec 21Tecan Group AG's (VTX:TECN) P/E Still Appears To Be Reasonable
Oct 09These 4 Measures Indicate That Tecan Group (VTX:TECN) Is Using Debt Reasonably Well
Sep 21Earnings Report: Tecan Group AG Missed Revenue Estimates By 8.8%
Aug 16Is Tecan Group (VTX:TECN) Using Too Much Debt?
Jun 14Calculating The Fair Value Of Tecan Group AG (VTX:TECN)
Apr 20Tecan Group AG's (VTX:TECN) Business Is Yet to Catch Up With Its Share Price
Apr 02Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Tecan Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 882 | -111 | 200 | 67 |
| 30 Sep 25 | 895 | -24 | 191 | 66 |
| 30 Jun 25 | 907 | 63 | 182 | 71 |
| 31 Mar 25 | 920 | 65 | 183 | 70 |
| 31 Dec 24 | 934 | 68 | 184 | 63 |
| 30 Sep 24 | 967 | 85 | 188 | 63 |
| 30 Jun 24 | 1,000 | 101 | 192 | 64 |
| 31 Mar 24 | 1,037 | 117 | 192 | 67 |
| 31 Dec 23 | 1,074 | 132 | 192 | 70 |
| 30 Sep 23 | 1,088 | 120 | 198 | 74 |
| 30 Jun 23 | 1,102 | 109 | 205 | 78 |
| 31 Mar 23 | 1,123 | 115 | 209 | 78 |
| 31 Dec 22 | 1,144 | 121 | 214 | 78 |
| 30 Sep 22 | 1,110 | 113 | 212 | 79 |
| 30 Jun 22 | 1,077 | 105 | 210 | 79 |
| 31 Mar 22 | 1,012 | 113 | 201 | 76 |
| 31 Dec 21 | 947 | 122 | 192 | 72 |
| 30 Sep 21 | 911 | 136 | 192 | 70 |
| 30 Jun 21 | 875 | 150 | 191 | 68 |
| 31 Mar 21 | 803 | 127 | 182 | 65 |
| 31 Dec 20 | 731 | 104 | 172 | 62 |
| 30 Sep 20 | 691 | 94 | 160 | 59 |
| 30 Jun 20 | 651 | 84 | 149 | 56 |
| 31 Mar 20 | 644 | 79 | 149 | 58 |
| 31 Dec 19 | 637 | 73 | 149 | 60 |
| 30 Sep 19 | 627 | 70 | 150 | 59 |
| 30 Jun 19 | 616 | 67 | 151 | 59 |
| 31 Mar 19 | 605 | 69 | 146 | 55 |
| 31 Dec 18 | 594 | 71 | 141 | 51 |
| 30 Sep 18 | 582 | 70 | 139 | 50 |
| 30 Jun 18 | 570 | 69 | 138 | 49 |
| 31 Mar 18 | 559 | 67 | 137 | 50 |
| 31 Dec 17 | 549 | 66 | 136 | 50 |
| 30 Sep 17 | 536 | 62 | 132 | 49 |
| 30 Jun 17 | 523 | 57 | 129 | 48 |
| 31 Mar 17 | 515 | 56 | 127 | 47 |
| 31 Dec 16 | 506 | 55 | 125 | 47 |
| 30 Sep 16 | 491 | 55 | 123 | 45 |
| 30 Jun 16 | 476 | 55 | 120 | 43 |
| 31 Mar 16 | 458 | 56 | 115 | 41 |
| 31 Dec 15 | 440 | 57 | 110 | 40 |
| 30 Sep 15 | 434 | 52 | 108 | 41 |
| 30 Jun 15 | 427 | 48 | 106 | 42 |
Quality Earnings: TECN is currently unprofitable.
Growing Profit Margin: TECN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TECN is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare TECN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TECN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (23.7%).
Return on Equity
High ROE: TECN has a negative Return on Equity (-9.61%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 01:55 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |